Agenus, Inc. Hits New 52-Week High at $8.65, Marking Significant Milestone

Agenus, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 8.65 on July 13, 2026. This achievement marks a notable rebound from its 52-week low of USD 2.71, showcasing a substantial increase in its stock price over the past year. Despite the recent uptick, Agenus has experienced a challenging year, with a performance decline of 64.36%, contrasting sharply with the S&P 500's gain of 20.06% during the same period. The company's market capitalization stands at approximately USD 130 million, reflecting its microcap status within the industry. Agenus currently operates without a dividend yield and has a negative price-to-book ratio of -0.48, indicating potential concerns regarding asset valuation. However, the company boasts a return on equity of 28.79%, suggesting effective management of equity despite its loss-making position. As the stock continues to navigate the complexities of the biotechnology landscape, this recent high could signal a pivotal moment in its market journey.